IP Library › Granted Patent US 12,496,333
Granted Patent B2
US 12,496,333 · App. 17/697,623 · Granted Dec 16, 2025

Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof

Inventor: Mads Hald Andersen (Naerum, DK)
Assignee: IO Biotech ApS
A61K39/001142A61K38/195A61K39/0011A61K48/00A61P35/00C07K14/521C12N15/85C12N15/86A61K40/4236
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,333
App. No.
17/697,623
Granted
Dec 16, 2025
Kind
B2
Abstract

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.

Claims (14)

1 . A nucleic acid encoding an immunogenically active CCL22 peptide fragment consisting of at the most 50 consecutive residues of SEQ ID NO: 12, wherein said peptide fragment is of at least 25 amino acids and contains a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 11.

2 . The nucleic acid according to claim 1 , wherein the peptide fragment comprises the sequence of SEQ ID NO: 5.

3 . A composition, comprising the nucleic acid of claim 1 .

4 . The composition of claim 3 , wherein the peptide fragment comprises the sequence of SEQ ID NO: 5.

5 . The composition of claim 3 , further comprising a nucleic acid encoding an immunogenically active protein or peptide fragment selected from a protein or peptide fragment, which is not CCL22.

6 . The composition of claim 3 , comprising an adjuvant.

7 . The composition of claim 6 , wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants and imidazoquinolines.

8 . The composition of claim 6 , wherein the adjuvant is a Montanide ISA adjuvant.

9 . The composition of claim 8 , wherein the adjuvant is Montanide ISA 51 or Montanide ISA 720.

10 . The composition of claim 9 , wherein the adjuvant is Montanide ISA 51.

11 . The composition of claim 6 , wherein the adjuvant is GM-CSF.

12 . The composition of claim 3 , wherein the nucleic acid is comprised within a vector.

13 . The composition of claim 12 , wherein the vector is selected from the group consisting of viral vectors and bacterial vectors.

14 . The composition of claim 12 , wherein the vector furthermore comprises nucleic acids encoding a T-cell stimulatory polypeptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: HERLEV HOSPITAL
To: IO BIOTECH APS
Reel/Frame 061415/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: ANDERSEN, MADS HALD
To: HERLEV HOSPITAL
Reel/Frame 061354/0980 →
Priority Claims (1)
DK PA 2015 70591 · Sep 16, 2015 · national
Continuity (3)
Continuation 15758187
Related Publication 20220280624A1 · Sep 8, 2022
Related Publication 20230241191A9 · Aug 3, 2023
References Cited (31)
US 7018627B1 · Gray et al. · 2006 [cited by applicant]
US 8563476B2 · Lillard, Jr. · 2013 [cited by applicant]
US 10130454B2 · Jones et al. · 2018 [cited by applicant]
US 10329336B2 · Yount et al. · 2019 [cited by applicant]
US 11298413B2 · Andersen · 2022 [cited by examiner]
US 11413245B2 · Little · 2022 [cited by applicant]
US 20060057112A1 · Gray et al. · 2006 [cited by applicant]
US 20070099844A1 · Prendergast et al. · 2007 [cited by applicant]
US 20140363495A1 · Schlom · 2014 [cited by examiner]
US 20220339273A1 · Andersen · 2022 [cited by applicant]
WO WO9640923A1 · 1996 [cited by applicant]
WO WO200078334A1 · 2000 [cited by applicant]
WO WO2009143843A1 · 2009 [cited by applicant]
WO WO2011139738A2 · 2011 [cited by applicant]
WO WO2013056716A1 · 2013 [cited by applicant]
WO WO2014028644A1 · 2014 [cited by applicant]
WO WO2014037811A2 · 2014 [cited by applicant]
WO WO2014170389A1 · 2014 [cited by applicant]
Comber et al. (2014) Ther. Adv. Vaccines, vol. 2(3), 77-89. [cited by examiner]
Purcell et al. (2007) Nature Rev., vol. 6, 404-414. [cited by examiner]
Calis et al. (2013) PLoS Comp. Biol., vol. 9(10), doi:10.1371/journal.pcbi.1003266, pp. 1-13. [cited by examiner]
Chang et al. (1997) J. Biol. Chem., vol. 272(4) 25229-25237. [cited by examiner]
American Cancer Society, “Signs and Symptoms of Cancer,” Nov. 6, 2020, 4 pages, retrieved from https://www.cancer.org/cancer/diagnosis-staging/signs-and-symptoms-of-cancer.html. [cited by applicant]
Cleeland, “Cancer-related Symptoms,” Seminars in Radiation Oncology, vol. 10, No. 3 Jul. 2000: pp. 175-190. [cited by applicant]
Harrington et al., “It's not over when it's over: long-term symptoms in cancer survivors—a systematic review,” Int J Psychiatry Med, 2010, vol. 40(2): 163-181. [cited by applicant]
Sabado et al., “Dendritic cell-based immunotherapy,” Cell Research (2017) 27:74-95. [cited by applicant]
Andersen MH et al., “Phosphorylated Peptides can be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL,” J Immunol, 163: 3812-3818, 1999. [cited by applicant]
Greenspan et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 1999, 7: 936-937. [cited by applicant]
Guo et al., “Macrophage-Derived Chemokine Gene Transfer Results in Tumor Regression in Murine Lung Carcinoma Model through Efficient Induction of Antitumor Immunity,” Gene Therapy, vol. 9, No. 12, 2002, 793-803. [cited by applicant]
Kovjazin et al., “The use of signal peptide domains as vaccine candidates,” Human Vaccines & Immunotherapeutics, Sep. 2014, 10:9, 2733-2740. [cited by applicant]
Qin et al, “CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion,” Clin Cancer Res. 15(7), 2231-2237, 2009. [cited by applicant]